NDAORALTABLET
Approved
Aug 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Mechanism of Action
Non-Nucleoside Reverse Transcriptase Inhibitors
Pharmacologic Class:
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
Clinical Trials (1)
The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patients
Started Nov 2023
18 enrolled
Hiv
Loss of Exclusivity
LOE Date
Nov 29, 2036
130 months away
Patent Expiry
Nov 29, 2036